FRAMINGHAM, MA, Firm that develops non-surgical treatments for common bladder disorders, has raised $7 million in equity financing.
for more funding data on Solace Therapeutics
To export Solace Therapeutics funding data to PDF and Excel, click here
Solace Therapeutics Inc., which develops non-surgical treatments for common bladder disorders, has raised $7 million in equity financing out of a $20 million offering, according to forms filed with the U.S. Securities and Exchange Commission.
Solace Therapeutics is an emerging medical device company that was formed to develop and commercialize non-surgical office-based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). These are very challenging and prevalent healthcare problems. Unfortunately, currently available therapies have significant side-effects and limited efficacy. The vast majority of patients, with quality-of-life as their highest priority, choose to "manage" their symptoms with absorbents. Solace is working to give these patients, and their healthcare providers, a compelling alternative.